# TGFβ2 siRNA (h): sc-39802



The Power to Question

#### **BACKGROUND**

Transforming growth factor  $\beta$ s (TGF $\beta$ s) were originally discovered due to their ability to promote anchorage-independent growth of rat NRK fibroblasts in the presence of TGF $\alpha$ . It is now realized that TGF $\beta$ s mediate many cell-cell interactions that occur during embryonic development. Three TGF $\beta$ s have been identified in mammals. TGF $\beta$ 1, TGF $\beta$ 2 and TGF $\beta$ 3 are each synthesized as precursor proteins that are very similar in that each is cleaved to yield a 112 amino acid polypeptide that remains associated with the latent portion of the molecules. Biologically active TGF $\beta$  requires dimerization of the monomers (usually homodimers) and release of the latent peptide portion. Overall, the mature region of the TGF $\beta$ 3 protein has approximately 80% identity to the mature region of both TGF $\beta$ 1 and TGF $\beta$ 2. However, the NH $_2$  terminals or precursor regions of their molecules share only 27% sequence identity.

## **REFERENCES**

- Todaro, G.J., et al. 1980. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc. Natl. Acad. Sci. USA 77: 5258-5262.
- 2. Anzano, M.A., et al. 1983. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type  $\alpha$  and type  $\beta$  transforming growth factors. Proc. Natl. Acad. Sci. USA 80: 6264-6268.
- 3. Derynck, R., et al. 1985. Human transforming growth factor- $\beta$  cDNA sequence and expression in tumor cell lines. Nature 316: 701-705.
- 2. deMartin, R., et al. 1987. Complementary DNA for human glioblastomaderived factor-β family. EMBO J. 6: 3673-3677.
- 3. ten Dijke, P., et al. 1988. Identification of a new member of the transforming growth factor type  $\beta$  gene family. Proc. Natl. Acad. Sci. USA 85: 4715-4719.

# CHROMOSOMAL LOCATION

Genetic locus: TGFB2 (human) mapping to 1q41.

# **PRODUCT**

TGFβ2 siRNA (h) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see TGFβ2 shRNA Plasmid (h): sc-39802-SH and TGFβ2 shRNA (h) Lentiviral Particles: sc-39802-V as alternate gene silencing products.

## STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

#### **APPLICATIONS**

TGF $\beta2$  siRNA (h) is recommended for the inhibition of TGF $\beta2$  expression in human cells.

## **SUPPORT REAGENTS**

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## **GENE EXPRESSION MONITORING**

TGF $\beta$ 2 (H-6): sc-374659 is recommended as a control antibody for monitoring of TGF $\beta$ 2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG $\kappa$  BP-FITC: sc-516140 or m-lgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

## **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor TGF $\beta$ 2 gene expression knockdown using RT-PCR Primer: TGF $\beta$ 2 (h)-PR: sc-39802-PR (20  $\mu$ l, 441 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

## **SELECT PRODUCT CITATIONS**

- Wei, Y.Y., et al. 2008. Osteoblasts-derived TGFβ1 enhance motility and integrin upregulation through Akt, ERK, and NFκB-dependent pathway in human breast cancer cells. Mol. Carcinog. 47: 526-537.
- 2. Li, B., et al. 2020. Bmi1 drives hepatocarcinogenesis by repressing the TGFβ2/Smad signalling axis. Oncogene 39: 1063-1079.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

## **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com